NEW YORK, March 19, 2026, 07:51 (EDT)
Eli Lilly shares grabbed attention Thursday, with the drugmaker reporting its experimental obesity and diabetes therapy, retatrutide, hit the primary endpoint in a late-stage trial—showing notable drops in both weight and blood sugar. The stock last changed hands at $918.05, off 1.3% early, after Tuesday’s nearly 6% tumble that followed a rare downgrade from HSBC.
Timing is a factor here. Investors are watching to see if Lilly can keep converting clinical successes into real growth, now that the obesity-drug focus has moved from supply constraints to pricing and reimbursement questions. The cash-pay segment—patients buying out of pocket, without insurance—adds another wrinkle. Lilly is also awaiting a U.S. ruling on orforglipron, its oral obesity candidate. Chief Financial Officer Lucas Montarce said earlier this month the drug was “on track in the US” and could hit the market as soon as the second quarter. Reuters
The stock now sits at a crossroads. Positive pipeline updates might shore up the Lilly story, though the commercial setup is less forgiving after Lilly and Novo Nordisk, under Trump-era deals, slashed U.S. cash prices for obesity shots to a range of $149 to $350 per month—well below the previous list price above $1,000.
Lilly reported its 40-week Phase 3 trial showed retatrutide lowered A1C by 1.7% to 2.0% depending on dose, compared to 0.8% with placebo. On the highest dose, patients dropped an average of 16.8% of their body weight—36.6 pounds—and Lilly noted weight loss hadn’t plateaued by the study’s end.
“For many people with type 2 diabetes, it is a struggle to achieve both A1C control and weight loss,” said Kenneth Custer, who heads Lilly Cardiometabolic Health. According to Custer, the data point to retatrutide’s “remarkable potential”—the drug is also under study for obesity, sleep apnea, and several other conditions. PR Newswire
The side effect profile tracked with what’s typical for this drug class. Lilly reported nausea, diarrhea, and vomiting as the leading issues—mostly cropping up during dose increases. Discontinuations due to side effects hit 5.1% for those on 12 mg, while nobody dropped out in the placebo arm. More granular data is slated for release at the American Diabetes Association meeting in June.
Novo still sets the standard here. The Danish drugmaker rolled out its oral Wegovy pill in the U.S. back in January, targeting self-pay patients. Lilly, on the other hand, says orforglipron could hit the market for shipping just about a week after it secures approval. That puts the next phase of rivalry squarely in the pill category rather than shots.
On Wall Street, not everyone is buying the stock’s growth pitch. Back in February, HSBC’s Rajesh Kumar flagged that prices had “come down quite sharply” and said higher volumes would be needed. Just this week, the bank cut its rating—a move that captured how swiftly sentiment can shift when price cuts and the cash-pay market make investors nervous. Reuters
The risk jumps out. Retatrutide remains experimental; Lilly warns there’s no promise that future studies or regulators will stick with what’s expected now. If orforglipron sees launch delays, side effect worries hit demand, or price cuts go deeper, Thursday’s results may end up mattering less for the stock than bulls hope.
